Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Blood (2022) 140 (Supplement 1): 186–188.

https://doi.org/10.1182/blood-2022-170381

Published: 2022

Journal Articles

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer Woyach, MD, Amy S. Ruppert, MAS, PhD, Gabriela Perez, MS, Allison M Booth, Diane Feldman, Elie G Dib, MD, Aminah Jatoi, MD, Jennifer Le-Rademacher, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Richard Little, MD, Wei Ding, MD PhD, Brian T. Hill, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1751.

https://doi.org/10.1182/blood-2019-127102

Published: 2019

Journal Articles

Long-Term Outcome of AIDS-Related Lymphoma Treated with Abbreviated Cycles of EPOCH-RR: A Prospective Study of 40 Patients

Kieron Dunleavy, MD, Richard Little, MD, Alan S. Wayne, MD, Nicole Grant, MPH, Stefania Pittaluga, MD, PhD, Elaine S. Jaffe, MD, Seth Steinberg, PhD, Robert Yarchoan, MD, PhD, Jorge A. Carrasquillo, MD, John E. Janik, MD, Wyndham H. Wilson, MD, PhD

Blood (2008) 112 (11): 3606.

https://doi.org/10.1182/blood.V112.11.3606.3606

Published: 2008

Journal Articles

Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.

Kieron Dunleavy, MD, Stefania Pittaluga, MD, John Janik, MD, Nicole Grant, MPH, Margaret Shovlin, RN, Richard Little, MD, Robert Yarchoan, MD, Seth Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 2736.

https://doi.org/10.1182/blood.V108.11.2736.2736

Published: 2006

Journal Articles

Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).

Kieron Dunleavy, MD, Alan S. Wayne, MD, Richard Little, MD, Nicole Grant, MPH, Seth Steinberg, PhD, Elaine S. Jaffe, MD, Stefania Pittaluga, MD, Robert Yarchoan, MD, Jorge Carrasquillo, MD, John Janik, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 2740.

https://doi.org/10.1182/blood.V108.11.2740.2740

Published: 2006

Journal Articles

The Addition of Rituximab to Dose-Adjusted EPOCH with HAART Suspension Is Highly Effective and Tolerable in AIDS-Related Lymphoma (ARL) and Allows the Delivery of Abbreviated Chemotherapy.

Kieron Dunleavy, MD, Alan Wayne, M.D, Richard Little, M.D, Nicole Grant, M.P.H., Seth Steinberg, Ph.D, Elaine S. Jaffe, MD, Stefania Pittaluga, MD, Robert Yarchoan, MD, Jorge Carrasquillo, MD, John Janik, MD, Wyndham H. Wilson, MD, PhD

Blood (2005) 106 (11): 930.

https://doi.org/10.1182/blood.V106.11.930.930

Published: 2005

Journal Articles

Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL).

Kieron Dunleavy, M.D., Richard Little, M.D., Juan Gea-Banacloche, M.D., Nicole Grant, M.P.H., Seth Steinberg, Ph.D., Robert Yarchoan, M.D., Stefania Pittaluga, M.D., Elaine Jaffe, M.D., John Janik, M.D., Wyndham H. Wilson, M.D., Ph.D.

Blood (2004) 104 (11): 3111.

https://doi.org/10.1182/blood.V104.11.3111.3111

Published: 2004

Journal Articles

Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome

Elizabeth M. Kang, Moniek de Witte, Harry Malech, Richard A. Morgan, Sheila Phang, Charles Carter, Susan F. Leitman, Richard Childs, A. John Barrett, Richard Little, John F. Tisdale

Blood (2002) 99 (2): 698–701.

https://doi.org/10.1182/blood.V99.2.698

Published: 2002

NARROW

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Long-Term Outcome of AIDS-Related Lymphoma Treated with Abbreviated Cycles of EPOCH-RR: A Prospective Study of 40 Patients

Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.

Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).

The Addition of Rituximab to Dose-Adjusted EPOCH with HAART Suspension Is Highly Effective and Tolerable in AIDS-Related Lymphoma (ARL) and Allows the Delivery of Abbreviated Chemotherapy.

Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL).

Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only